File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy

TitleProspective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy
Authors
Issue Date1997
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ohns
Citation
Otolaryngology - Head And Neck Surgery, 1997, v. 116 n. 2, p. 189-192 How to Cite?
AbstractThe aim of this study is to compare the efficacy of a thrice weekly 6- month regimen, 4S3H3R3Z3/2H3R3 (which consists of an initial 4 months of streptomycin (S), isoniazid (H), rifampicin (R), and pyrazinamide (Z) followed by 2 months of isoniazid and rifampicin), with o thrice weekly 9- month regimen, 4S3H3R3Z3/5H3R3 (which consists of an initial 4 months of streptomycin, isoniazid, rifampicin, and pyrazinamide followed by 5 months of isoniazid and rifampicin), in the treatment of cervical tuberculous lymphadenopathy. A total of 113 patients were recruited between August 1987 and December 1993. Twenty-two patients were excluded from the analysis because of defaulting treatment or modification of regimen. Ninety- one patients were included in the analysis. Forty-three patients were given the 6-month regimen, and 48 patients were given the 9-month regimen. Two (5%) patients of the 6-month regimen and one (2%) patient of the 9-month regimen had primary failure after completion of treatment (relative risk, 2.23; 95% confidence interval, 0.21 to 23.76). Of the 88 patients who had initial clinical remission after completion of treatment, the 5-year actuarial remission rates were 89% for the 6-month regimen and 90% for the 9-month regimen (Wilcoxon, p = 0.44). There were no significant differences of both primary failure rate and 5-year actuarial remission rate of the two regimens. The 6-month regimen is recommended as the initial treatment of tuberculous lymphadenopathy.
Persistent Identifierhttp://hdl.handle.net/10722/83351
ISSN
2015 Impact Factor: 2.021
2015 SCImago Journal Rankings: 1.176
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYuen, APWen_HK
dc.contributor.authorWong, SHWen_HK
dc.contributor.authorCheuk Ming Tam, Cen_HK
dc.contributor.authorShiu Lun Chanen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorSai Kit Lauen_HK
dc.date.accessioned2010-09-06T08:40:00Z-
dc.date.available2010-09-06T08:40:00Z-
dc.date.issued1997en_HK
dc.identifier.citationOtolaryngology - Head And Neck Surgery, 1997, v. 116 n. 2, p. 189-192en_HK
dc.identifier.issn0194-5998en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83351-
dc.description.abstractThe aim of this study is to compare the efficacy of a thrice weekly 6- month regimen, 4S3H3R3Z3/2H3R3 (which consists of an initial 4 months of streptomycin (S), isoniazid (H), rifampicin (R), and pyrazinamide (Z) followed by 2 months of isoniazid and rifampicin), with o thrice weekly 9- month regimen, 4S3H3R3Z3/5H3R3 (which consists of an initial 4 months of streptomycin, isoniazid, rifampicin, and pyrazinamide followed by 5 months of isoniazid and rifampicin), in the treatment of cervical tuberculous lymphadenopathy. A total of 113 patients were recruited between August 1987 and December 1993. Twenty-two patients were excluded from the analysis because of defaulting treatment or modification of regimen. Ninety- one patients were included in the analysis. Forty-three patients were given the 6-month regimen, and 48 patients were given the 9-month regimen. Two (5%) patients of the 6-month regimen and one (2%) patient of the 9-month regimen had primary failure after completion of treatment (relative risk, 2.23; 95% confidence interval, 0.21 to 23.76). Of the 88 patients who had initial clinical remission after completion of treatment, the 5-year actuarial remission rates were 89% for the 6-month regimen and 90% for the 9-month regimen (Wilcoxon, p = 0.44). There were no significant differences of both primary failure rate and 5-year actuarial remission rate of the two regimens. The 6-month regimen is recommended as the initial treatment of tuberculous lymphadenopathy.en_HK
dc.languageengen_HK
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ohnsen_HK
dc.relation.ispartofOtolaryngology - Head and Neck Surgeryen_HK
dc.rightsOtolaryngology - Head and Neck Surgery. Copyright © Mosby, Inc.en_HK
dc.titleProspective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0194-5998&volume=116&spage=189&epage=192&date=1997&atitle=Prospective+randomized+study+of+thrice+weekly+six-month+and+nine-month+chemotherapy+for+cervical+tuberculous+lymphadenopathyen_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0194-5998(97)70323-1en_HK
dc.identifier.pmid9051062-
dc.identifier.scopuseid_2-s2.0-0031028346en_HK
dc.identifier.hkuros23900en_HK
dc.identifier.volume116en_HK
dc.identifier.issue2en_HK
dc.identifier.spage189en_HK
dc.identifier.epage192en_HK
dc.identifier.isiWOS:A1997WJ76600009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, APW=7006290111en_HK
dc.identifier.scopusauthoridWong, SHW=13302920800en_HK
dc.identifier.scopusauthoridCheuk Ming Tam, C=17033781900en_HK
dc.identifier.scopusauthoridShiu Lun Chan=17036791700en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridSai Kit Lau=7409597138en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats